-
1
-
-
79953176289
-
Boceprevir for previously treated chronic hcv genotype 1 infection
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207-1217. http://dx.doi.org/10.1056/ NEJMoa1009482.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
Burroughs, M.11
Brass, C.A.12
Albrecht, J.K.13
Esteban, R.14
-
2
-
-
79959381354
-
Telaprevir for retreatment of hcv infection
-
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364: 2417-2428. http://dx.doi.org/10.1056/ NEJMoa1013086.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
Younossi, Z.8
Foster, G.R.9
Horban, A.10
Ferenci, P.11
Nevens, F.12
Mullhaupt, B.13
Pockros, P.14
Terg, R.15
Shouval, D.16
Van Hoek, B.17
Weiland, O.18
Van Heeswijk, R.19
De Meyer, S.20
Luo, D.21
Boogaerts, G.22
Polo, R.23
Picchio, G.24
Beumont, M.25
more..
-
3
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis c virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Ferenci, P.9
Flisiak, R.10
George, J.11
Rizzetto, M.12
Shouval, D.13
Sola, R.14
Terg, R.A.15
Yoshida, E.M.16
Adda, N.17
Bengtsson, L.18
Sankoh, A.J.19
Kieffer, T.L.20
George, S.21
Kauffman, R.S.22
Zeuzem, S.23
more..
-
4
-
-
79953173221
-
Boceprevir for untreated chronic hcv genotype 1 infection
-
Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364: 1195-1206. http://dx.doi.org/10. 1056/NEJMoa1010494.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
Reddy, K.R.8
Goodman, Z.D.9
Boparai, N.10
DiNubile, M.J.11
Sniukiene, V.12
Brass, C.A.13
Albrecht, J.K.14
Bronowicki, J.P.15
-
5
-
-
84880309916
-
Understanding the hepatitis c virus life cycle paves the way for highly effective therapies
-
Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http://dx.doi.org/10.1038/nm.3248.
-
(2013)
Nat. Med.
, vol.19
, pp. 837-849
-
-
Scheel, T.K.1
Rice, C.M.2
-
6
-
-
84874107832
-
Perspectives and challenges of interferonfree therapy for chronic hepatitis c
-
Lange CM, Zeuzem S. 2013. Perspectives and challenges of interferonfree therapy for chronic hepatitis C. J. Hepatol. 58:583-592. http://dx.doi.org/10. 1016/j.jhep.2012.10.019.
-
(2013)
J. Hepatol.
, vol.58
, pp. 583-592
-
-
Lange, C.M.1
Zeuzem, S.2
-
8
-
-
84881314351
-
Novel therapies for hepatitisc one pill fits all?
-
Manns MP, von HT. 2013. Novel therapies for hepatitisC-one pill fits all? Nat. Rev. Drug Discov. 12:595-610. http://dx.doi.org/10.1038/nrd4050.
-
(2013)
Nat. Rev. Drug Discov.
, vol.12
, pp. 595-610
-
-
Manns, M.P.1
Von, H.T.2
-
9
-
-
0032876683
-
Crystal structure of the rna-dependent rna polymerase from hepatitis c virus reveals a fully encircled active site
-
Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943. http://dx.doi.org/10.1038/13305.
-
(1999)
Nat. Struct. Biol.
, vol.6
, pp. 937-943
-
-
Lesburg, C.A.1
Cable, M.B.2
Ferrari, E.3
Hong, Z.4
Mannarino, A.F.5
Weber, P.C.6
-
10
-
-
0025249362
-
Hepatitis c virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups
-
Miller RH, Purcell RH. 1990. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl. Acad. Sci. U. S. A. 87:2057-2061. http://dx.doi.org/10.1073/pnas.87.6.2057.
-
(1990)
Proc. Natl. Acad. Sci. U. S. A.
, vol.87
, pp. 2057-2061
-
-
Miller, R.H.1
Purcell, R.H.2
-
11
-
-
84876286638
-
Hepatitis c virus therapy update 2013
-
Casey LC, Lee WM. 2013. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 29:243-249. http://dx.doi.org/10.1097/MOG.0b013e32835ff972.
-
(2013)
Curr. Opin. Gastroenterol.
, vol.29
, pp. 243-249
-
-
Casey, L.C.1
Lee, W.M.2
-
12
-
-
84856410313
-
Antiviral strategies in hepatitis c virus infection
-
Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl 1):S88-S100. http://dx.doi.org/10.1016/S0168-8278(12)60010-5.
-
(2012)
J. Hepatol.
, vol.56
, Issue.SUPPL. 1
-
-
Sarrazin, C.1
Hezode, C.2
Zeuzem, S.3
Pawlotsky, J.M.4
-
13
-
-
84876582239
-
Treatment of chronic hepatitis c: Current and future
-
Pawlotsky JM. 2013. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 369:321-342. http://dx.doi.org/10.1007/978-3- 642-27340-7-13.
-
(2013)
Curr. Top. Microbiol. Immunol.
, vol.369
, pp. 321-342
-
-
Pawlotsky, J.M.1
-
14
-
-
84880934969
-
Interferon free regimens for the"difficult-to-treat": Are we there?
-
Londoño MC, Lens S, Forns X. 2013. Interferon free regimens for the "difficult-to-treat": are we there? J. Hepatol. 58:643-645. http://dx.doi.org/10.1016/j.jhep.2013.01.007.
-
(2013)
J. Hepatol.
, vol.58
, pp. 643-645
-
-
Londoño, M.C.1
Lens, S.2
Forns, X.3
-
15
-
-
84855246805
-
Future treatment of chronic hepatitis c with direct acting antivirals: Is resistance important?
-
Halfon P, Sarrazin C. 2012. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 32(Suppl 1):79-87. http://dx.doi.org/10.1111/j.1478-3231.2011.02716.x.
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 79-87
-
-
Halfon, P.1
Sarrazin, C.2
-
16
-
-
79955103901
-
Treatment failure and resistance with direct-Acting antiviral drugs against hepatitis c virus
-
Pawlotsky JM. 2011. Treatment failure and resistance with direct-Acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751. http://dx.doi.org/10.1002/hep.24262.
-
(2011)
Hepatology
, vol.53
, pp. 1742-1751
-
-
Pawlotsky, J.M.1
-
17
-
-
84855544169
-
An updated analysis of hepatitis c virus genotypes and subtypes based on the complete coding region
-
Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 32:339-345. http://dx.doi.org/10.1111/j.1478-3231. 2011.02684.x.
-
(2012)
Liver Int.
, vol.32
, pp. 339-345
-
-
Nakano, T.1
Lau, G.M.2
Lau, G.M.3
Sugiyama, M.4
Mizokami, M.5
-
18
-
-
61549118827
-
Nomenclature and numbering of the hepatitis c virus
-
Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10.1007/978-1-59745-394- 3-4.
-
(2009)
Methods Mol. Biol.
, vol.510
, pp. 33-53
-
-
Kuiken, C.1
Simmonds, P.2
-
19
-
-
58149388300
-
Naturally occurring dominant resistance mutations to hepatitis c virus protease and polymerase inhibitors in treatment-naive patients
-
Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778. http://dx.doi.org/10.1002/ hep.22549.
-
(2008)
Hepatology
, vol.48
, pp. 1769-1778
-
-
Kuntzen, T.1
Timm, J.2
Berical, A.3
Lennon, N.4
Berlin, A.M.5
Young, S.K.6
Lee, B.7
Heckerman, D.8
Carlson, J.9
Reyor, L.L.10
Kleyman, M.11
McMahon, C.M.12
Birch, C.13
Schulze Zur Wiesch, J.14
Ledlie, T.15
Koehrsen, M.16
Kodira, C.17
Roberts, A.D.18
Lauer, G.M.19
Rosen, H.R.20
Bihl, F.21
Cerny, A.22
Spengler, U.23
Liu, Z.24
Kim, A.Y.25
Xing, Y.26
Schneidewind, A.27
Madey, M.A.28
Fleckenstein, J.F.29
Park, V.M.30
Galagan, J.E.31
Nusbaum, C.32
Walker, B.D.33
Lake-Bakaar, G.V.34
Daar, E.S.35
Jacobson, I.M.36
Gomperts, E.D.37
Edlin, B.R.38
Donfield, S.M.39
Chung, R.T.40
Talal, A.H.41
Marion, T.42
Birren, B.W.43
Henn, M.R.44
Allen, T.M.45
more..
-
20
-
-
51749123143
-
Natural prevalence of hepatitis c virus variants with decreased sensitivity to ns3.4a protease inhibitors in treatment-naive subjects
-
Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198:800-807. http://dx.doi.org/10. 1086/591141.
-
(2008)
J. Infect. Dis.
, vol.198
, pp. 800-807
-
-
Bartels, D.J.1
Zhou, Y.2
Zhang, E.Z.3
Marcial, M.4
Byrn, R.A.5
Pfeiffer, T.6
Tigges, A.M.7
Adiwijaya, B.S.8
Lin, C.9
Kwong, A.D.10
Kieffer, T.L.11
-
21
-
-
77954598121
-
A multi-variant, viral dynamic model of genotype 1 hcv to assess the in vivo evolution of protease-inhibitor resistant variants
-
Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle JC, Sarrazin C, Zeuzem S, Caron PR. 2010. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 6:e1000745. http://dx.doi.org/10.1371/ journal.pcbi.1000745.
-
(2010)
PLoS Comput. Biol.
, vol.6
-
-
Adiwijaya, B.S.1
Herrmann, E.2
Hare, B.3
Kieffer, T.4
Lin, C.5
Kwong, A.D.6
Garg, V.7
Randle, J.C.8
Sarrazin, C.9
Zeuzem, S.10
Caron, P.R.11
-
22
-
-
84873041135
-
Hepatitis c virus variants with decreased sensitivity to direct-Acting antivirals (daas) were rarely observed in daa-naive patients prior to treatment
-
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. 2013. Hepatitis C virus variants with decreased sensitivity to direct-Acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J. Virol. 87:1544-1553. http://dx.doi.org/10.1128/JVI.02294-12.
-
(2013)
J. Virol.
, vol.87
, pp. 1544-1553
-
-
Bartels, D.J.1
Sullivan, J.C.2
Zhang, E.Z.3
Tigges, A.M.4
Dorrian, J.L.5
De Meyer, S.6
Takemoto, D.7
Dondero, E.8
Kwong, A.D.9
Picchio, G.10
Kieffer, T.L.11
-
23
-
-
84877580079
-
The presence of resistance mutations to protease and polymerase inhibitors in hepatitis c virus sequences from the los alamos databank
-
Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, de Carvalho IM. 2013. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamos databank. J. Viral Hepat. 20:414-421. http://dx.doi.org/10.1111/jvh. 12051.
-
(2013)
J. Viral Hepat.
, vol.20
, pp. 414-421
-
-
Alves, R.1
Queiroz, A.T.2
Pessoa, M.G.3
Da Silva, E.F.4
Mazo, D.F.5
Carrilho, F.J.6
Carvalho-Filho, R.J.7
De Carvalho, I.M.8
-
24
-
-
81855199759
-
Impact of antiretroviral therapy on the variability of the hcv ns5b polymerase in hiv/hcv co-infected patients
-
Plaza Z, Soriano V, Gonzalez MM, Di Lello FA, Macias J, Labarga P, Pineda JA, Poveda E. 2011. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. J. Antimicrob. Chemother. 66:2838-2842. http://dx.doi.org/10.1093/jac/dkr385.
-
(2011)
J. Antimicrob. Chemother.
, vol.66
, pp. 2838-2842
-
-
Plaza, Z.1
Soriano, V.2
Gonzalez, M.M.3
Di Lello, F.A.4
Macias, J.5
Labarga, P.6
Pineda, J.A.7
Poveda, E.8
-
25
-
-
84858421432
-
Drug resistance testing in hepatitis c therapy
-
Poveda E, Soriano V. 2012. Drug resistance testing in hepatitis C therapy. Future Virol. 7:309-321. http://dx.doi.org/10.2217/fvl.12.13.
-
(2012)
Future Virol.
, vol.7
, pp. 309-321
-
-
Poveda, E.1
Soriano, V.2
-
26
-
-
84867500308
-
Development of global consensus sequence and analysis of highly conserved domains of the hcv ns5b protein
-
Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M. 2012. Development of global consensus sequence and analysis of highly conserved domains of the HCV NS5B protein. Hepat. Mon. 12:e6142. http://dx.doi.org/10.5812/hepatmon.6142.
-
(2012)
Hepat. Mon.
, vol.12
-
-
Waheed, Y.1
Saeed, U.2
Anjum, S.3
Afzal, M.S.4
Ashraf, M.5
-
27
-
-
84863663083
-
Hcv genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
-
Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. 2012. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 7:e39652. http://dx.doi.org/10.1371/ journal.pone.0039652.
-
(2012)
PLoS One
, vol.7
-
-
Cento, V.1
Mirabelli, C.2
Salpini, R.3
Dimonte, S.4
Artese, A.5
Costa, G.6
Mercurio, F.7
Svicher, V.8
Parrotta, L.9
Bertoli, A.10
Ciotti, M.11
Di Paolo, D.12
Sarrecchia, C.13
Andreoni, M.14
Alcaro, S.15
Angelico, M.16
Perno, C.F.17
Ceccherini-Silberstein, F.18
-
28
-
-
79957613599
-
Mega5: Molecular evolutionary genetics analysis using maximum likeli-hood, evolutionary distance, and maximum parsimony methods
-
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likeli-hood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
-
(2011)
Mol. Biol. Evol.
, vol.28
, pp. 2731-2739
-
-
Tamura, K.1
Peterson, D.2
Peterson, N.3
Stecher, G.4
Nei, M.5
Kumar, S.6
-
29
-
-
34247573851
-
Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis c ns5b polymerase
-
Nittoli T, Curran K, Insaf S, DiGrandi M, Orlowski M, Chopra R, Agarwal A, Howe AY, Prashad A, Floyd MB, Johnson B, Sutherland A, Wheless K, Feld B, O'Connell J, Mansour TS, Bloom J. 2007. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. J. Med. Chem. 50:2108-2116. http://dx.doi.org/10.1021/jm061428x.
-
(2007)
J. Med. Chem.
, vol.50
, pp. 2108-2116
-
-
Nittoli, T.1
Curran, K.2
Insaf, S.3
DiGrandi, M.4
Orlowski, M.5
Chopra, R.6
Agarwal, A.7
Howe, A.Y.8
Prashad, A.9
Floyd, M.B.10
Johnson, B.11
Sutherland, A.12
Wheless, K.13
Feld, B.14
O'Connell, J.15
Mansour, T.S.16
Bloom, J.17
-
30
-
-
84877776880
-
Beyond telaprevir and boceprevir: Resistance and new agents for hepatitis c virus infection
-
Wyles DL. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top. Antivir. Med. 20:139-145.
-
(2012)
Top. Antivir. Med.
, vol.20
, pp. 139-145
-
-
Wyles, D.L.1
-
31
-
-
84867253952
-
Antiviral resistance and directacting antiviral agents for hcv
-
Aloia AL, Locarnini S, Beard MR. 2012. Antiviral resistance and directacting antiviral agents for HCV. Antivir. Ther. 17:1147-1162. http://dx.doi.org/10.3851/IMP2426.
-
(2012)
Antivir. Ther.
, vol.17
, pp. 1147-1162
-
-
Aloia, A.L.1
Locarnini, S.2
Beard, M.R.3
-
32
-
-
84861109960
-
Genotype and subtype profiling of psi-7977 as a nucleotide inhibitor of hepatitis c virus
-
Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. 2012. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56:3359-3368. http://dx.doi.org/10.1128/AAC.00054- 12.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 3359-3368
-
-
Lam, A.M.1
Espiritu, C.2
Bansal, S.3
Micolochick Steuer, H.M.4
Niu, C.5
Zennou, V.6
Keilman, M.7
Zhu, Y.8
Lan, S.9
Otto, M.J.10
Furman, P.A.11
-
33
-
-
84861655785
-
Resistance to mericitabine, a nucleoside analogue inhibitor of hcv rna-dependent rna polymerase
-
Pawlotsky JM, Najera I, Jacobson I. 2012. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir. Ther. 17:411-423. http://dx.doi.org/10.3851/IMP2088.
-
(2012)
Antivir. Ther.
, vol.17
, pp. 411-423
-
-
Pawlotsky, J.M.1
Najera, I.2
Jacobson, I.3
-
34
-
-
84898617692
-
Preclinical and in vitro resistance profile of potent nucleotide polymerase inhibitors of hcv: Als-2200 and its single diastereomer, vx-135, abstr o-02. Abstr
-
Boston, MA
-
Tan H, Jekle A, Kang H, Moy C, Deval J, Jin Z, Jiang M, Ardzinski A, Dyatkina N, Chanda SM, Kieffer TL, Blatt LM, Beigelman L, Smith DB, Symons JA. 2013. Preclinical and in vitro resistance profile of potent nucleotide polymerase inhibitors of HCV: ALS-2200 and its single diastereomer, VX-135, abstr O-02. Abstr. 8th Internat Wksp Hep C Resist New Compounds, Boston, MA.
-
(2013)
8th Internat Wksp Hep C Resist New Compounds
-
-
Tan, H.1
Jekle, A.2
Kang, H.3
Moy, C.4
Deval, J.5
Jin, Z.6
Jiang, M.7
Ardzinski, A.8
Dyatkina, N.9
Chanda, S.M.10
Kieffer, T.L.11
Blatt, L.M.12
Beigelman, L.13
Smith, D.B.14
Symons, J.A.15
-
35
-
-
84862696759
-
Rapid and strong antiviral activity of the non-nucleosidic ns5b polymerase inhibitor bi 207127 in combination with peginterferon alfa 2a and ribavirin
-
Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arasteh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Bocher W, Steffgen J. 2012. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J. Hepatol. 57:39-46. http://dx.doi.org/10.1016/j.jhep.2012.02.015.
-
(2012)
J. Hepatol.
, vol.57
, pp. 39-46
-
-
Larrey, D.1
Lohse, A.W.2
De Ledinghen, V.3
Trepo, C.4
Gerlach, T.5
Zarski, J.P.6
Tran, A.7
Mathurin, P.8
Thimme, R.9
Arasteh, K.10
Trautwein, C.11
Cerny, A.12
Dikopoulos, N.13
Schuchmann, M.14
Heim, M.H.15
Gerken, G.16
Stern, J.O.17
Wu, K.18
Abdallah, N.19
Girlich, B.20
Scherer, J.21
Berger, F.22
Marquis, M.23
Kukolj, G.24
Bocher, W.25
Steffgen, J.26
more..
-
36
-
-
84884245458
-
Antiviral effect, safety, and pharmacokinetics of 5 days' oral administration of deleobuvir (bi 207127), an investigational hcv rna polymerase inhibitor, in patients with chronic hepatitis c
-
Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arasteh K, Bourliere M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G. 2013. Antiviral effect, safety, and pharmacokinetics of 5 days' oral administration of deleobuvir (BI 207127), an investigational HCV RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob. Agents Chemother. 57:4727-4735. http://dx.doi.org/10.1128/AAC.00565-13.
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 4727-4735
-
-
Larrey, D.1
Lohse, A.W.2
Trepo, C.3
Bronowicki, J.P.4
Arasteh, K.5
Bourliere, M.6
Calleja, J.L.7
Stern, J.O.8
Nehmiz, G.9
Abdallah, N.10
Berger, K.L.11
Marquis, M.12
Steffgen, J.13
Kukolj, G.14
-
37
-
-
84865442445
-
Tmc647055, a potent nonnucleoside hepatitis c virus ns5b polymerase inhibitor with cross-genotypic coverage
-
Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI. 2012. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob. Agents Chemother. 56:4676-4684. http://dx.doi.org/10.1128/AAC.00245-12.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 4676-4684
-
-
Devogelaere, B.1
Berke, J.M.2
Vijgen, L.3
Dehertogh, P.4
Fransen, E.5
Cleiren, E.6
Van Der Helm, L.7
Nyanguile, O.8
Tahri, A.9
Amssoms, K.10
Lenz, O.11
Cummings, M.D.12
Clayton, R.F.13
Vendeville, S.14
Raboisson, P.15
Simmen, K.A.16
Fanning, G.C.17
Lin, T.I.18
-
38
-
-
84873054024
-
Characterization of viral escape in hcv genotype 1-infected patients treated with bms-791325 and pegylated interferon-Alfa and ribavirin
-
McPhee F, Falk P, Fracasso P, Lemm J, Liu M, Kirk M, Hernandez D, Cooney E, Hughes E, Gao M. 2012. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-Alfa and ribavirin. J. Hepatol. 56(Suppl 2):S473. http://dx.doi.org/10.1016/S0168- 8278(12)61206-9.
-
(2012)
J. Hepatol.
, vol.56
, Issue.SUPPL. 2
-
-
McPhee, F.1
Falk, P.2
Fracasso, P.3
Lemm, J.4
Liu, M.5
Kirk, M.6
Hernandez, D.7
Cooney, E.8
Hughes, E.9
Gao, M.10
-
39
-
-
84857186976
-
Characterization of resistance to the nonnucleoside ns5b inhibitor filibuvir in hepatitis c virus-infected patients
-
Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. 2012. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob. Agents Chemother. 56:1331-1341. http://dx.doi.org/10.1128/AAC.05611-11.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 1331-1341
-
-
Troke, P.J.1
Lewis, M.2
Simpson, P.3
Gore, K.4
Hammond, J.5
Craig, C.6
Westby, M.7
-
40
-
-
84898604018
-
Characterization of hcv variants in genotype 1 patients administered vx-222, a non-nucleoside polymerase inhibitor, abstr o-10. Abstr
-
Boston, MA
-
Bartels DJ, Jiang M, Zhang E, Tigges A, Sullivan J, Dorrian J, Spanks J, Ardzinski A, Nicolas O, Bedard J, Kwong A, Kieffer T. 2010. Characterization of HCV variants in genotype 1 patients administered VX-222, a non-nucleoside polymerase inhibitor, abstr O-10. Abstr. 5th Internat Wksp Hep C Resist New Compounds, Boston, MA.
-
(2010)
5th Internat Wksp Hep C Resist New Compounds
-
-
Bartels, D.J.1
Jiang, M.2
Zhang, E.3
Tigges, A.4
Sullivan, J.5
Dorrian, J.6
Spanks, J.7
Ardzinski, A.8
Nicolas, O.9
Bedard, J.10
Kwong, A.11
Kieffer, T.12
-
41
-
-
79952139742
-
Resistance profile of abt-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days
-
Middleton T, He Y, Beyer J, Menon R, Klein CE, Cohen D, Collins C. 2010. Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days. J. Hepatol. 52(Suppl 1):S296-S297. http://dx.doi.org/10.1016/S0168-8278(10) 60764-7.
-
(2010)
J. Hepatol.
, vol.52
, Issue.SUPPL. 1
-
-
Middleton, T.1
He, Y.2
Beyer, J.3
Menon, R.4
Klein, C.E.5
Cohen, D.6
Collins, C.7
-
42
-
-
84872848108
-
Preclinical characterization of gs-9669, a thumb site ii inhibitor of the hepatitis c virus ns5b polymerase
-
Fenaux M, Eng S, Leavitt SA, Lee YJ, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, Xu L, Ye H, Zhang J, Matles M, Murray BP, Mwangi J, Zhang J, Hashash A, Krawczyk SH, Bidgood AM, Appleby TC, Watkins WJ. 2013. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57:804-810. http://dx.doi.org/10. 1128/AAC.02052-12.
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 804-810
-
-
Fenaux, M.1
Eng, S.2
Leavitt, S.A.3
Lee, Y.J.4
Mabery, E.M.5
Tian, Y.6
Byun, D.7
Canales, E.8
Clarke, M.O.9
Doerffler, E.10
Lazerwith, S.E.11
Lew, W.12
Liu, Q.13
Mertzman, M.14
Morganelli, P.15
Xu, L.16
Ye, H.17
Zhang, J.18
Matles, M.19
Murray, B.P.20
Mwangi, J.21
Zhang, J.22
Hashash, A.23
Krawczyk, S.H.24
Bidgood, A.M.25
Appleby, T.C.26
Watkins, W.J.27
more..
-
43
-
-
75149195123
-
In vitro studies demonstrate that combinations of antiviral agents that include hcv polymerase inhibitor ana598 have the potential to overcome viral resistance
-
Thompson PA, Patel RA, Showalter RE, Li C, Appleman JR, Steffy KR. 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology 48(Suppl):1164A.
-
(2008)
Hepatology
, vol.48
, Issue.SUPPL.
-
-
Thompson, P.A.1
Patel, R.A.2
Showalter, R.E.3
Li, C.4
Appleman, J.R.5
Steffy, K.R.6
-
44
-
-
80051820156
-
Mechanistic characterization of gs-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis c virus ns5b polymerase
-
Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55:4196-4203. http://dx.doi.org/10.1128/AAC.00307-11.
-
(2011)
Antimicrob. Agents Chemother.
, vol.55
, pp. 4196-4203
-
-
Shih, I.H.1
Vliegen, I.2
Peng, B.3
Yang, H.4
Hebner, C.5
Paeshuyse, J.6
Purstinger, G.7
Fenaux, M.8
Tian, Y.9
Mabery, E.10
Qi, X.11
Bahador, G.12
Paulson, M.13
Lehman, L.S.14
Bondy, S.15
Tse, W.16
Reiser, H.17
Lee, W.A.18
Schmitz, U.19
Neyts, J.20
Zhong, W.21
more..
-
45
-
-
84856440468
-
Emergence and persistence of ns5b mutations following combination treatment with tegobuvir (gs-9190) plus standard of care-long-term follow-up from the phase iib study gs-us-1960103
-
Hebner C, Harris J, Oldach D, Miller MD, Mo H. 2011. Emergence and persistence of NS5B mutations following combination treatment with tegobuvir (GS-9190) plus standard of care-long-term follow-up from the phase IIB study GS-US-1960103. J. Hepatol. 54(Suppl 1):S18-S19. http://dx.doi.org/10.1016/S0168- 8278(11)61213-0.
-
(2011)
J. Hepatol.
, vol.54
, Issue.SUPPL. 1
-
-
Hebner, C.1
Harris, J.2
Oldach, D.3
Miller, M.D.4
Mo, H.5
-
46
-
-
84898612101
-
Patterns of ns5b mutations in a 3-day clinical trial of hcv non-nucleoside polymerase inhibitor idx375
-
McCarville J, Gillum JM, Seifer M, Dumbrava VT, Pietropaolo K, Sullivan-Bolyai J, Strandring DN. 2011. Patterns of NS5B mutations in a 3-day clinical trial of HCV non-nucleoside polymerase inhibitor IDX375. Hepatology 54(Suppl S1):542A.
-
(2011)
Hepatology
, vol.54
, Issue.SUPPL. S1
-
-
McCarville, J.1
Gillum, J.M.2
Seifer, M.3
Dumbrava, V.T.4
Pietropaolo, K.5
Sullivan-Bolyai, J.6
Strandring, D.N.7
-
47
-
-
80055092755
-
Role of hepatitis b virus genetic barrier in drug-resistance and immune-escape development
-
Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. 2011. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig. Liver Dis. 43:975-983. http://dx.doi.org/10. 1016/j.dld.2011.07.002.
-
(2011)
Dig. Liver Dis.
, vol.43
, pp. 975-983
-
-
Svicher, V.1
Cento, V.2
Salpini, R.3
Mercurio, F.4
Fraune, M.5
Beggel, B.6
Han, Y.7
Gori, C.8
Wittkop, L.9
Bertoli, A.10
Micheli, V.11
Gubertini, G.12
Longo, R.13
Romano, S.14
Visca, M.15
Gallinaro, V.16
Marino, N.17
Mazzotta, F.18
De Sanctis, G.M.19
Fleury, H.20
Trimoulet, P.21
Angelico, M.22
Cappiello, G.23
Zhang, X.X.24
Verheyen, J.25
Ceccherini-Silberstein, F.26
Perno, C.F.27
more..
-
48
-
-
33645098601
-
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different hiv-1 subtypes
-
van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van LK, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2006. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41:352-360. http://dx.doi.org/10.1097/01.qai.0000209899.05126.e4.
-
(2006)
J. Acquir. Immune Defic. Syndr.
, vol.41
, pp. 352-360
-
-
Van De Vijver, D.A.1
Wensing, A.M.2
Angarano, G.3
Asjo, B.4
Balotta, C.5
Boeri, E.6
Camacho, R.7
Chaix, M.L.8
Costagliola, D.9
De Luca, A.10
Derdelinckx, I.11
Grossman, Z.12
Hamouda, O.13
Hatzakis, A.14
Hemmer, R.15
Hoepelman, A.16
Horban, A.17
Korn, K.18
Kucherer, C.19
Leitner, T.20
Loveday, C.21
MacRae, E.22
Maljkovic, I.23
De Mendoza, C.24
Meyer, L.25
Nielsen, C.26
Op De Coul, E.L.27
Ormaasen, V.28
Paraskevis, D.29
Perrin, L.30
Puchhammer-Stockl, E.31
Ruiz, L.32
Salminen, M.33
Schmit, J.C.34
Schneider, F.35
Schuurman, R.36
Soriano, V.37
Stanczak, G.38
Stanojevic, M.39
Vandamme, A.M.40
Van, L.K.41
Violin, M.42
Wilbe, K.43
Yerly, S.44
Zazzi, M.45
Boucher, C.A.46
more..
-
49
-
-
0033954256
-
The protein data bank
-
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242. http://dx.doi.org/10.1093/nar/28.1.235.
-
(2000)
Nucleic Acids Res.
, vol.28
, pp. 235-242
-
-
Berman, H.M.1
Westbrook, J.2
Feng, Z.3
Gilliland, G.4
Bhat, T.N.5
Weissig, H.6
Shindyalov, I.N.7
Bourne, P.E.8
-
50
-
-
79953270504
-
Investigation of the mode of binding of a novel series of n-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis c virus polymerase
-
Gentles RG, Sheriff S, Beno BR, Wan C, Kish K, Ding M, Zheng X, Chupak L, Poss MA, Witmer MR, Morin P, Wang YK, Rigat K, Lemm J, Voss S, Liu M, Pelosi L, Roberts SB, Gao M, Kadow JF. 2011. Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2- carboxamides to the hepatitis C virus polymerase. Bioorg. Med. Chem. Lett. 21:2212-2215. http://dx.doi.org/10.1016/j.bmcl.2011.03.011.
-
(2011)
Bioorg. Med. Chem. Lett.
, vol.21
, pp. 2212-2215
-
-
Gentles, R.G.1
Sheriff, S.2
Beno, B.R.3
Wan, C.4
Kish, K.5
Ding, M.6
Zheng, X.7
Chupak, L.8
Poss, M.A.9
Witmer, M.R.10
Morin, P.11
Wang, Y.K.12
Rigat, K.13
Lemm, J.14
Voss, S.15
Liu, M.16
Pelosi, L.17
Roberts, S.B.18
Gao, M.19
Kadow, J.F.20
more..
-
51
-
-
36448991500
-
Clustal w and clustal x version 2.0
-
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. http://dx.doi.org/10.1093/bioinformatics/btm404.
-
(2007)
Bioinformatics
, vol.23
, pp. 2947-2948
-
-
Larkin, M.A.1
Blackshields, G.2
Brown, N.P.3
Chenna, R.4
McGettigan, P.A.5
McWilliam, H.6
Valentin, F.7
Wallace, I.M.8
Wilm, A.9
Lopez, R.10
Thompson, J.D.11
Gibson, T.J.12
Higgins, D.G.13
-
52
-
-
25144517646
-
Integrated modeling program, applied chemical theory (impact
-
Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, Repasky MP, Zhang LY, Berne BJ, Friesner RA, Gallicchio E, Levy RM. 2005. Integrated modeling program, applied chemical theory (IMPACT). J. Comput. Chem. 26:1752-1780. http://dx.doi.org/10. 1002/jcc.20292.
-
(2005)
J. Comput. Chem.
, vol.26
, pp. 1752-1780
-
-
Banks, J.L.1
Beard, H.S.2
Cao, Y.3
Cho, A.E.4
Damm, W.5
Farid, R.6
Felts, A.K.7
Halgren, T.A.8
Mainz, D.T.9
Maple, J.R.10
Murphy, R.11
Philipp, D.M.12
Repasky, M.P.13
Zhang, L.Y.14
Berne, B.J.15
Friesner, R.A.16
Gallicchio, E.17
Levy, R.M.18
-
53
-
-
0344778061
-
Semianalytical treatment of solvation for molecular mechanics and dynamics
-
Still WC, Tempezyk A, Hawley RC, Hendrickson T. 1990. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 112:6127-6129. http://dx.doi.org/10.1021/ja00172a038.
-
(1990)
J. Am. Chem. Soc.
, vol.112
, pp. 6127-6129
-
-
Still, W.C.1
Tempezyk, A.2
Hawley, R.C.3
Hendrickson, T.4
-
54
-
-
20344403522
-
Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (qm/mm)approach
-
Cho AE, Guallar V, Berne BJ, Friesner R. 2005. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM)approach. J. Comput. Chem. 26:915-931. http://dx.doi.org/10.1002/jcc. 20222.
-
(2005)
J. Comput. Chem.
, vol.26
, pp. 915-931
-
-
Cho, A.E.1
Guallar, V.2
Berne, B.J.3
Friesner, R.4
-
55
-
-
82955197340
-
Docking analysis and resistance evaluation of clinically relevant mutations associated with the hiv-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine
-
Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V. 2011. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. ChemMedChem 6:2203-2213. http://dx.doi.org/10.1002/ cmdc.201100362.
-
(2011)
ChemMedChem
, vol.6
, pp. 2203-2213
-
-
Alcaro, S.1
Alteri, C.2
Artese, A.3
Ceccherini-Silberstein, F.4
Costa, G.5
Ortuso, F.6
Bertoli, A.7
Forbici, F.8
Santoro, M.M.9
Parrotta, L.10
Flandre, P.11
Masquelier, B.12
Descamps, D.13
Calvez, V.14
Marcelin, A.G.15
Perno, C.F.16
Sing, T.17
Svicher, V.18
-
56
-
-
84860143899
-
The polymorphisms of dna g-quadruplex investigated by docking experiments with telomestatin enantiomers
-
Alcaro S, Costa G, Distinto S, Moraca F, Ortuso F, Parrotta L, Artese A. 2012. The polymorphisms of DNA G-quadruplex investigated by docking experiments with telomestatin enantiomers. Curr. Pharm. Des. 18:1873-1879. http://dx.doi.org/10.2174/138161212799958495.
-
(2012)
Curr. Pharm. Des.
, vol.18
, pp. 1873-1879
-
-
Alcaro, S.1
Costa, G.2
Distinto, S.3
Moraca, F.4
Ortuso, F.5
Parrotta, L.6
Artese, A.7
-
57
-
-
84874337197
-
Detecting and understanding genetic and structural features in hiv-1 b subtype v3 underlying hiv-1 co-receptor usage
-
Chen M, Svicher V, Artese A, Costa G, Alteri C, Ortuso F, Parrotta L, Liu Y, Liu C, Perno CF, Alcaro S, Zhang J. 2013. Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. Bioinformatics 29:451-460. http://dx.doi.org/10.1093/ bioinformatics/btt002.
-
(2013)
Bioinformatics
, vol.29
, pp. 451-460
-
-
Chen, M.1
Svicher, V.2
Artese, A.3
Costa, G.4
Alteri, C.5
Ortuso, F.6
Parrotta, L.7
Liu, Y.8
Liu, C.9
Perno, C.F.10
Alcaro, S.11
Zhang, J.12
-
58
-
-
84855994429
-
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase b
-
Distinto S, Yanez M, Alcaro S, Cardia MC, Gaspari M, Sanna ML, Meleddu R, Ortuso F, Kirchmair J, Markt P, Bolasco A, Wolber G, Secci D, Maccioni E. 2012. Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B. Eur. J. Med. Chem. 48:284-295. http://dx.doi.org/10.1016/j.ejmech.2011.12.027.
-
(2012)
Eur. J. Med. Chem.
, vol.48
, pp. 284-295
-
-
Distinto, S.1
Yanez, M.2
Alcaro, S.3
Cardia, M.C.4
Gaspari, M.5
Sanna, M.L.6
Meleddu, R.7
Ortuso, F.8
Kirchmair, J.9
Markt, P.10
Bolasco, A.11
Wolber, G.12
Secci, D.13
Maccioni, E.14
-
59
-
-
79960651250
-
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors
-
Gaspar A, Silva T, Yanez M, Vina D, Orallo F, Ortuso F, Uriarte E, Alcaro S, Borges F. 2011. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J. Med. Chem. 54:5165-5173. http://dx.doi.org/10. 1021/jm2004267.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 5165-5173
-
-
Gaspar, A.1
Silva, T.2
Yanez, M.3
Vina, D.4
Orallo, F.5
Ortuso, F.6
Uriarte, E.7
Alcaro, S.8
Borges, F.9
-
60
-
-
78649329129
-
Synthesis and biological evaluation of n-substituted-3,5-diphenyl-2- pyrazoline derivatives as cyclooxygenase (cox-2) inhibitors
-
Fioravanti R, Bolasco A, Manna F, Rossi F, Orallo F, Ortuso F, Alcaro S, Cirilli R. 2010. Synthesis and biological evaluation of N-substituted-3,5- diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. Eur. J. Med. Chem. 45:6135-6138. http://dx.doi.org/10.1016/j.ejmech.2010.10.005.
-
(2010)
Eur. J. Med. Chem.
, vol.45
, pp. 6135-6138
-
-
Fioravanti, R.1
Bolasco, A.2
Manna, F.3
Rossi, F.4
Orallo, F.5
Ortuso, F.6
Alcaro, S.7
Cirilli, R.8
-
61
-
-
77950638598
-
Rational design, syn thesis, biophysical and antiproliferative evaluation of fluorenone derivatives with dna g-quadruplex binding properties
-
Alcaro S, Artese A, Iley JN, Missailidis S, Ortuso F, Parrotta L, Pasceri R, Paduano F, Sissi C, Trapasso F, Vigorita MG. 2010. Rational design, synthesis, biophysical and antiproliferative evaluation of fluorenone derivatives with DNA G-quadruplex binding properties. ChemMedChem 5:575-583. http://dx.doi.org/10.1002/cmdc.200900541.
-
(2010)
ChemMedChem
, vol.5
, pp. 575-583
-
-
Alcaro, S.1
Artese, A.2
Iley, J.N.3
Missailidis, S.4
Ortuso, F.5
Parrotta, L.6
Pasceri, R.7
Paduano, F.8
Sissi, C.9
Trapasso, F.10
Vigorita, M.G.11
-
62
-
-
84873167874
-
Rna dependent rna polymerase of hcv: A potential target for the development of antiviral drugs
-
Waheed Y, Bhatti A, Ashraf M. 2013. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs. Infect. Genet. Evol. 14:247-257. http://dx.doi.org/10.1016/j.meegid.2012.12.004.
-
(2013)
Infect. Genet. Evol.
, vol.14
, pp. 247-257
-
-
Waheed, Y.1
Bhatti, A.2
Ashraf, M.3
-
63
-
-
0033571463
-
Crystal structure of the rna-dependent rna polymerase of hepatitis c virus
-
Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426. http://dx.doi.org/10.1016/S0969-2126(00)80031-3.
-
(1999)
Structure
, vol.7
, pp. 1417-1426
-
-
Ago, H.1
Adachi, T.2
Yoshida, A.3
Yamamoto, M.4
Habuka, N.5
Yatsunami, K.6
Miyano, M.7
-
65
-
-
66149115122
-
Crystal structure of a novel dimeric form of ns5a domain i protein from hepatitis c virus
-
Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403. http://dx.doi.org/10.1128/JVI.02352-08.
-
(2009)
J. Virol.
, vol.83
, pp. 4395-4403
-
-
Love, R.A.1
Brodsky, O.2
Hickey, M.J.3
Wells, P.A.4
Cronin, C.N.5
-
66
-
-
0036120573
-
Structural analysis of the hepatitis c virus rna polymerase in complex with ribonucleotides
-
Bressanelli S, Tomei L, Rey FA, De Francesco R. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492. http://dx.doi.org/10.1128/JVI.76.7.3482-3492.2002.
-
(2002)
J. Virol.
, vol.76
, pp. 3482-3492
-
-
Bressanelli, S.1
Tomei, L.2
Rey, F.A.3
De Francesco, R.4
-
67
-
-
0035120615
-
Mutational analysis of the structure and functions of hepatitis c virus rna-dependent rna polymerase
-
Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Murakami S. 2001. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 33:728-737. http://dx.doi.org/10.1053/jhep.2001.22765.
-
(2001)
Hepatology
, vol.33
, pp. 728-737
-
-
Qin, W.1
Yamashita, T.2
Shirota, Y.3
Lin, Y.4
Wei, W.5
Murakami, S.6
-
68
-
-
84857639534
-
Characterization of viral resistance mutations in genotype 1 hcv patients receiving combination therapy with protease inhibitor and a polymerase inhibitor with or without ribavirin
-
Mo H, Hebner C, Han B, Harris A, Bae K, Wong W, Delaney W, Oldach D, Miller MD. 2011. Characterization of viral resistance mutations in genotype 1 HCV patients receiving combination therapy with protease inhibitor and a polymerase inhibitor with or without ribavirin. J. Hepatol. 54(Suppl 1):S484. http://dx.doi.org/10.1016/S0168-8278(11)61227-0.
-
(2011)
J. Hepatol.
, vol.54
, Issue.SUPPL. 1
-
-
Mo, H.1
Hebner, C.2
Han, B.3
Harris, A.4
Bae, K.5
Wong, W.6
Delaney, W.7
Oldach, D.8
Miller, M.D.9
-
69
-
-
20944447120
-
Replication fitness and ns5b drug sensitivity of diverse hepatitis c virus isolates characterized by using a transient replication assay
-
Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, Lafemina RL. 2005. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49:2059-2069. http://dx.doi.org/10.1128/AAC.49.5.2059-2069.2005.
-
(2005)
Antimicrob. Agents Chemother.
, vol.49
, pp. 2059-2069
-
-
Ludmerer, S.W.1
Graham, D.J.2
Boots, E.3
Murray, E.M.4
Simcoe, A.5
Markel, E.J.6
Grobler, J.A.7
Flores, O.A.8
Olsen, D.B.9
Hazuda, D.J.10
Lafemina, R.L.11
-
70
-
-
69849107011
-
Naturally occurring substitutions conferring resistance to hepatitis c virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5
-
Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J. 2009. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5. Antivir. Ther. 14:723-730.
-
(2009)
Antivir. Ther.
, vol.14
, pp. 723-730
-
-
Legrand-Abravanel, F.1
Henquell, C.2
Le Guillou-Guillemette, H.3
Balan, V.4
Mirand, A.5
Dubois, M.6
Lunel-Fabiani, F.7
Payan, C.8
Izopet, J.9
-
71
-
-
35748953422
-
Advances in the development of new therapeutic agents targeting the ns3-4a serine protease or the ns5b rna-dependent rna polymerase of the hepatitis c virus
-
De Francesco R, Carfi A. 2007. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59:1242-1262. http://dx.doi.org/10.1016/j.addr.2007.04.016.
-
(2007)
Adv. Drug Deliv. Rev.
, vol.59
, pp. 1242-1262
-
-
De Francesco, R.1
Carfi, A.2
-
72
-
-
11144231108
-
Inhibitors of the hcv ns5b polymerase: New hope for the treatment of hepatitis c infections
-
Beaulieu PL, Tsantrizos YS. 2004. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs 5:838-850.
-
(2004)
Curr. Opin. Investig. Drugs
, vol.5
, pp. 838-850
-
-
Beaulieu, P.L.1
Tsantrizos, Y.S.2
-
73
-
-
84872045978
-
Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2 and 3: The electron trial
-
Gane EJ, Stedman CA, Hyland RH, Pang PS, Sorensen RD, Symonds W, Hindes RD, Berrey MM. 2012. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON Trial. 63rd Annu. Meet. Am. Assoc. Study Liver Dis. Hepatology 56(Suppl S1):306A-307A.
-
(2012)
63rd Annu. Meet. Am. Assoc. Study Liver Dis Hepatology
, vol.56
, Issue.SUPPL. S1
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
Pang, P.S.4
Sorensen, R.D.5
Symonds, W.6
Hindes, R.D.7
Berrey, M.M.8
-
74
-
-
84877739274
-
Sofosbuvir for hepatitis c genotype 2 or 3 in patients without treatment options
-
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368:1867-1877. http://dx.doi.org/10.1056/NEJMoa1214854.
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 1867-1877
-
-
Jacobson, I.M.1
Gordon, S.C.2
Kowdley, K.V.3
Yoshida, E.M.4
Rodriguez-Torres, M.5
Sulkowski, M.S.6
Shiffman, M.L.7
Lawitz, E.8
Everson, G.9
Bennett, M.10
Schiff, E.11
Al-Assi, M.T.12
Subramanian, G.M.13
An, D.14
Lin, M.15
McNally, J.16
Brainard, D.17
Symonds, W.T.18
McHutchison, J.G.19
Patel, K.20
Feld, J.21
Pianko, S.22
Nelson, D.R.23
more..
-
75
-
-
84867398802
-
The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
-
Gotte M. 2012. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr. Opin. Virol. 2:644-650. http://dx.doi.org/10.1016/j.coviro.2012.08.004.
-
(2012)
Curr. Opin. Virol.
, vol.2
, pp. 644-650
-
-
Gotte, M.1
-
76
-
-
84855509792
-
Contribution of a mutational bias in hepatitis c virus replication to the genetic barrier in the development of drug resistance
-
Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H, Kouyos RD, Gotte M. 2011. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:20509-20513. http://dx.doi.org/10.1073/pnas.1105797108.
-
(2011)
Proc. Natl. Acad. Sci. U. S. A.
, vol.108
, pp. 20509-20513
-
-
Powdrill, M.H.1
Tchesnokov, E.P.2
Kozak, R.A.3
Russell, R.S.4
Martin, R.5
Svarovskaia, E.S.6
Mo, H.7
Kouyos, R.D.8
Gotte, M.9
-
77
-
-
61849176462
-
Genetic barriers for integrase inhibitor drug resistance in hiv type-1 b and crf02ag subtypes
-
Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cisse M, Katlama C, Calvez V, Marcelin AG. 2009. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02AG subtypes. Antivir. Ther. 14:123-129.
-
(2009)
Antivir. Ther.
, vol.14
, pp. 123-129
-
-
Maiga, A.I.1
Malet, I.2
Soulie, C.3
Derache, A.4
Koita, V.5
Amellal, B.6
Tchertanov, L.7
Delelis, O.8
Morand-Joubert, L.9
Mouscadet, J.F.10
Murphy, R.11
Cisse, M.12
Katlama, C.13
Calvez, V.14
Marcelin, A.G.15
-
78
-
-
28244461263
-
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis c virus ns5b polymerase
-
Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, Gauthier J, Goulet S, Poupart MA, Beaulieu PL. 2005. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280:39260-39267. http://dx.doi.org/10.1074/jbc.M506407200.
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 39260-39267
-
-
Kukolj, G.1
McGibbon, G.A.2
McKercher, G.3
Marquis, M.4
Lefebvre, S.5
Thauvette, L.6
Gauthier, J.7
Goulet, S.8
Poupart, M.A.9
Beaulieu, P.L.10
-
79
-
-
10744221995
-
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis c virus rna-dependent rna polymerase
-
Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R, Migliaccio G. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77: 13225-13231. http://dx.doi.org/10. 1128/JVI.77.24.13225-13231.2003.
-
(2003)
J. Virol.
, vol.77
, pp. 13225-13231
-
-
Tomei, L.1
Altamura, S.2
Bartholomew, L.3
Biroccio, A.4
Ceccacci, A.5
Pacini, L.6
Narjes, F.7
Gennari, N.8
Bisbocci, M.9
Incitti, I.10
Orsatti, L.11
Harper, S.12
Stansfield, I.13
Rowley, M.14
De Francesco, R.15
Migliaccio, G.16
-
80
-
-
84871765489
-
Exploratory study of oral combination antiviral therapy for hepatitis c
-
Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. 2013. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 368:45-53. http://dx.doi.org/10.1056/NEJMoa1208809.
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 45-53
-
-
Poordad, F.1
Lawitz, E.2
Kowdley, K.V.3
Cohen, D.E.4
Podsadecki, T.5
Siggelkow, S.6
Heckaman, M.7
Larsen, L.8
Menon, R.9
Koev, G.10
Tripathi, R.11
Pilot-Matias, T.12
Bernstein, B.13
-
81
-
-
33744910421
-
In vitro selected con1 subgenomic replicons resistant to 2=-cmethyl-cytidine or to r1479 show lack of cross resistance
-
Le Pogam S, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, Jiang S, Singer M, Ali S, Klumpp K, Smith D, Symons J, Cammack N, Najera I. 2006. In vitro selected Con1 subgenomic replicons resistant to 2=-Cmethyl-cytidine or to R1479 show lack of cross resistance. Virology 351: 349-359. http://dx.doi.org/ 10.1016/j.virol.2006.03.045.
-
(2006)
Virology
, vol.351
, pp. 349-359
-
-
Le Pogam, S.1
Jiang, W.R.2
Leveque, V.3
Rajyaguru, S.4
Ma, H.5
Kang, H.6
Jiang, S.7
Singer, M.8
Ali, S.9
Klumpp, K.10
Smith, D.11
Symons, J.12
Cammack, N.13
Najera, I.14
-
82
-
-
33845247515
-
General catalytic deficiency of hepatitis c virus rna polymerase with an s282t mutation and mutually exclusive resistance towards 2=-modified nucleotide analogues
-
Dutartre H, Bussetta C, Boretto J, Canard B. 2006. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2=-modified nucleotide analogues. Antimicrob. Agents Chemother. 50:4161-4169. http://dx.doi.org/10.1128/AAC.00433- 06.
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, pp. 4161-4169
-
-
Dutartre, H.1
Bussetta, C.2
Boretto, J.3
Canard, B.4
-
83
-
-
57049112290
-
Selected replicon variants with low-level in vitro resistance to the hepatitis c virus ns5b polymerase inhibitor psi-6130 lack crossresistance with r1479
-
Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WR. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack crossresistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369. http://dx.doi.org/10.1128/AAC.00444- 08.
-
(2008)
Antimicrob. Agents Chemother.
, vol.52
, pp. 4356-4369
-
-
Ali, S.1
Leveque, V.2
Le Pogam, S.3
Ma, H.4
Philipp, F.5
Inocencio, N.6
Smith, M.7
Alker, A.8
Kang, H.9
Najera, I.10
Klumpp, K.11
Symons, J.12
Cammack, N.13
Jiang, W.R.14
-
84
-
-
1542677267
-
Characterization of resistance to non-obligate chainterminating ribonucleoside analogs that inhibit hepatitis c virus replication in vitro
-
Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, Lafemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA. 2003. Characterization of resistance to non-obligate chainterminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170. http://dx.doi.org/10.1074/jbc.M305041200.
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 49164-49170
-
-
Migliaccio, G.1
Tomassini, J.E.2
Carroll, S.S.3
Tomei, L.4
Altamura, S.5
Bhat, B.6
Bartholomew, L.7
Bosserman, M.R.8
Ceccacci, A.9
Colwell, L.F.10
Cortese, R.11
De Francesco, R.12
Eldrup, A.B.13
Getty, K.L.14
Hou, X.S.15
Lafemina, R.L.16
Ludmerer, S.W.17
MacCoss, M.18
McMasters, D.R.19
Stahlhut, M.W.20
Olsen, D.B.21
Hazuda, D.J.22
Flores, O.A.23
more..
-
85
-
-
84898647381
-
Evolution of the hcv viral population from one patient with s282t detected at relapse after sofosbuvir monotherapy
-
Hedskog C, Gontcharova V, Han B, Martin R, Miller MD, Mo H, Svarovskaia ES. 2013. Evolution of the HCV viral population from one patient with S282T detected at relapse after sofosbuvir monotherapy. Antivir. Ther. 18(Suppl 1):A9.
-
(2013)
Antivir. Ther.
, vol.18
, Issue.SUPPL. 1
-
-
Hedskog, C.1
Gontcharova, V.2
Han, B.3
Martin, R.4
Miller, M.D.5
Mo, H.6
Svarovskaia, E.S.7
-
86
-
-
84866119318
-
Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive hcv genotype 1-infected patients
-
Gane EJ, Pockros P, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Yetzer ES, Shulman N, Tong X, Najera I, Bertasso A, Hammond J, Stancic S. 2012. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients. J. Hepatol. 56(Suppl 2):S555-S556. http://dx.doi.org/10.1016/S0168-8278(12) 61423-8.
-
(2012)
J. Hepatol.
, vol.56
, Issue.SUPPL. 2
-
-
Gane, E.J.1
Pockros, P.2
Zeuzem, S.3
Marcellin, P.4
Shikhman, A.5
Bernaards, C.6
Yetzer, E.S.7
Shulman, N.8
Tong, X.9
Najera, I.10
Bertasso, A.11
Hammond, J.12
Stancic, S.13
-
87
-
-
84866177809
-
Quantifying the diversification of hepatitis c virus (hcv) during primary infection: Estimates of the in vivo mutation rate
-
Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, Shaw GM, Perelson AS. 2012. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8:e1002881. http://dx.doi.org/10. 1371/journal.ppat.1002881.
-
(2012)
PLoS Pathog.
, vol.8
-
-
Ribeiro, R.M.1
Li, H.2
Wang, S.3
Stoddard, M.B.4
Learn, G.H.5
Korber, B.T.6
Bhattacharya, T.7
Guedj, J.8
Parrish, E.H.9
Hahn, B.H.10
Shaw, G.M.11
Perelson, A.S.12
-
88
-
-
65449157987
-
Hepatitis c virus drug resistance and immunedriven adaptations: Relevance to new antiviral therapy
-
Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. 2009. Hepatitis C virus drug resistance and immunedriven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082. http://dx.doi.org/10.1002/hep. 22773.
-
(2009)
Hepatology
, vol.49
, pp. 1069-1082
-
-
Gaudieri, S.1
Rauch, A.2
Pfafferott, K.3
Barnes, E.4
Cheng, W.5
McCaughan, G.6
Shackel, N.7
Jeffrey, G.P.8
Mollison, L.9
Baker, R.10
Furrer, H.11
Gunthard, H.F.12
Freitas, E.13
Humphreys, I.14
Klenerman, P.15
Mallal, S.16
James, I.17
Roberts, S.18
Nolan, D.19
Lucas, M.20
more..
-
89
-
-
84880359255
-
A boceprevir failure in a patient infected with hcv genotype 1g: Importance and limitations of virus genotyping prior to hcv protease-inhibitor- based therapy
-
Cento V, Landonio S, De Luca F, Di Maio VC, Micheli V, Mirabelli C, Niero F, Magni C, Rizzardini G, Perno CF, Ceccherini-Silberstein F. 2013. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir. Ther. 18:645-648. http://dx.doi.org/10.3851/IMP2529.
-
(2013)
Antivir. Ther.
, vol.18
, pp. 645-648
-
-
Cento, V.1
Landonio, S.2
De Luca, F.3
Di Maio, V.C.4
Micheli, V.5
Mirabelli, C.6
Niero, F.7
Magni, C.8
Rizzardini, G.9
Perno, C.F.10
Ceccherini-Silberstein, F.11
|